View Full Report

Summary

The company reports strong financial, social and environmental performance for 2009

Report Highlights

Novo Nordisk reports strong financial, social and environmental performance for 2009

Despite continuing challenges in the global economic environment, 2009 was a successful year for Novo Nordisk, the global leader in diabetes care. The company’s accomplishments during the year, including strong performance against social and environmental targets, are reported in its sixth annual integrated report.

During 2009, Novo Nordisk:
Increased sales by 11% (in local currencies) and by 12% in Danish kroner to DKK 51,078 million compared to 2008.
Increased reported operating profit by 21% to DKK 14,933 million compared to 2008.
Reduced CO2 emissions by 32% and water consumption by 20%.
Increased its workforce by 8% to 29,329 employees.
Expanded support for healthcare capacity building in developing countries by donating 82 million DKK to the World Diabetes Foundation and the Novo Nordisk Haemophilia Foundation.
Diagnosed and enrolled more than 400 children with type 1 diabetes in the Changing Diabetes® in Children programme, which builds sustainable partnerships to expand access to care.

Novo Nordisk manages its business using the Triple Bottom Line principle to ensure that decision-making balances profitability with long-term societal interests. The integrated Annual Report 2009 seeks to meet the information needs of all stakeholders.

In the absence of global standards for inclusive reporting, the Annual Report 2009 was prepared in respect of international standards for mandatory and voluntary reporting:

International Financial Reporting Standards (IFRS).
The accountability standard, the AA1000 (2008) Framework, which includes AA1000APS(2008) and AA1000AS(2008).
Global Reporting Initiative (GRI) G3 Sustainability Reporting Guidelines.
UN Global Compact, Communication on Progress.
US Sarbanes-Oxley Act requirements for financial reporting. Novo Nordisk has also embarked on a process of aligning the control environment for non-financial data with the control environment for financial data.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
require_once 'counter/results/hit.php'; //hits counter do not remove
?>